US8663708B2 - Product of vegetal origin comprising proanthocyanidines and its preparation process - Google Patents
Product of vegetal origin comprising proanthocyanidines and its preparation process Download PDFInfo
- Publication number
- US8663708B2 US8663708B2 US11/571,237 US57123705A US8663708B2 US 8663708 B2 US8663708 B2 US 8663708B2 US 57123705 A US57123705 A US 57123705A US 8663708 B2 US8663708 B2 US 8663708B2
- Authority
- US
- United States
- Prior art keywords
- product
- water
- vegetal
- vegetal origin
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- This invention relates to the field of the pharmaceutical, dietary and food industries, in particular to products related to the control of risk factors of cardiovascular diseases.
- a high level of cholesterol in the blood is a risk factor for cardiovascular disease.
- Different studies have demonstrated that people who consume diets rich in fiber have lower amounts of cholesterol and LDL in the blood than people who consume less fiber (cf. M. H. Davidson et al., “Effect of hydroxypropylmethylcellulose on serum lipids in subjects with mild-to-moderate primary hypercholesterolemia”, J. Am Col Card, 1998, vol. 31(2) Suppl. A:319A).
- the beneficial effects of fiber are also known for protecting intestinal barrier integrity and preventing colon cancer.
- Dietary fibers contain some pharmacologically active compounds, but they mainly contain products with little or no activity, such as celluloses or hemicelluloses.
- Minority components of the dietary fiber are polyphenols.
- the term polyphenol covers a large number of secondary metabolites of vegetables, which are structurally characterized by having aromatic rings with hydroxyl groups. In plants, polyphenols can be found free or associated to components of the cellular wall. This localization, together with their molecular weight, allows for differentiation between soluble and insoluble polyphenols. Insoluble polyphenols have a greater molecular weight and have the beneficial health effects indicated above.
- insoluble polyphenolic compounds are present in small amounts in fiber of the most commonly consumed vegetables or in commercial dietary supplements of fiber. Moreover, most of these insoluble polyphenols are not usable in their natural state in the necessary doses for chronic treatment of degenerative diseases, because they have a strong astringent and anti-nutritional effects due to the inhibition activity of the digestive enzymes, which form complexes with proteins.
- carob bean fiber from the fruit of the carob tree ( Ceratonia Siliqua ).
- carob fiber One commercial fiber with a high polyphenol content is called “carob fiber”, of C.G.A. S.A. (cf. ES 2,060,543).
- carob bean fiber Another carob bean fiber is described in the patent document ES 2,204,301. Both fibers have a polyphenol content of approximately 50% of the dry weight. These fibers reduce cholesterol levels in rats, but extrapolation to a human scale of the doses used in studies with animals would require amounts between 25 and 50 g/day, which are very high doses for therapeutic use.
- Attempts have been made to increase the insoluble polyphenol content in dietary fiber is a carob bean fiber containing nearly 90% of insoluble polyphenols that have been thermally modified in order to eliminate their astringent and anti-nutritional effects (cf. ES 2.187.356).
- a dietary fiber with a high percentage of insoluble polyphenols with the aim of producing a maximum hypocholesterolaemic effect at acceptable doses for human consumption and with low astringent and antinutritional effects. It is also desirable to provide industrially viable processes for preparation of such dietary fiber.
- the product of vegetal origin may comprises about 65-97% percent by weight of proanthocyanidines with a molecular weight greater than 6000 daltons, wherein more than about 50% percent by weight of said proanthocyanidines may have a molecular weight greater than 30000 daltons.
- the percent by weight of the proanthocyanidines with molecular weight greater than 6000 daltons may be about 90-97%.
- the percent by weight of the proanthocyanidines with molecular weight greater than 30000 daltons versus the proanthocyanidines with molecular weight greater than 6000 daltons may be higher than about 60%.
- proanthocyanidine is considered to be a synonym of the term “condensed tannin”, as both are chemically polymerized derivatives of flavonoids, mainly of flavan-3-ol. Thus, both are a type of high molecular weight polyphenol.
- the product of vegetal origin indicated above may further comprise about 0-2% percent by weight, and particularly about 0-1% by weight, of cold water-soluble polyphenols.
- composition of the product of vegetal origin is as follows:
- the product of vegetal origin of the present invention generally takes the form of a brown amorphous powder. It is not very soluble in water and in low molecular weight alcohols at room temperature. Its solubility rises when the temperature is close to the boiling point of the solvent or of the solvent mixture. These solutions give a positive reaction of polyphenols with Folin-Ciocalteau reactive and a precipitation with lead salts.
- the product of vegetal origin is a product mainly indigestible and non-absorbable in the mammalian or human intestinal tract.
- the proanthocyanidines Due to the chemical structure of the proanthocyanidines present in the product of the invention, the proanthocyanidines produce a hydrophobic-type interaction with cholesterol and bile salts, which are then eliminated through feces as complexes with said proanthocyanidines. Therefore, the enterohepatic cycle of cholesterol and bile salts is interrupted and thus, cholesterol diminishes in the organism. Due to the enrichment in proanthocyanidines with high molecular weight, the product of vegetal origin of the invention produces a maximum hipocholesterolaemic effect at acceptable doses for human consume, usable in a pharmaceutical form, and with low astringent and anti-nutritional effects.
- the product may be obtained from dicotyledons. It may be obtained from the whole plant or from parts of it, including fruits in a ripe state and preferably dried fruits. Plants and their fruits may be collected in a ripe state, generally at the end of summer, and may be left to dry in the shade at room temperature and at low relative humidity conditions.
- Examples of appropriate vegetal varieties that may be used for the preparation of the product of the invention are lucerne ( Medicago sativa ), field eryngo ( Eryngium campestre ), holm oak bark ( Quercus ilex ), pomegranate tree ( Punica granatum ) and quebracho ( Aspindosperma quebracho - bianco ).
- Examples of fruits that may be used are carob bean ( Ceratonia siliqua ), fruit from walnut tree ( Juglans regia ), olive ( Olea europea ), blueberry ( Vaccinuium myrtillus ), pomegranate ( Punica granatum ) and apple ( Pyrus malus ).
- the product of the invention is obtained from pomegranate or from carob bean pulp.
- the preparation process of the product of vegetal origin described above may comprise the steps of: (a) performing a wash of the crushed vegetal material with a liquid selected from the group consisting of water between about room temperature and 60° C.; a mixture of water and a C 1 -C 3 alcohol between about 20:80 and about 5:95 (v/v) at about room temperature; and a mixture of water and acetone between about 20:80 and about 40:60 (v/v) at about room temperature; and separating the solid and the liquid resulting from the wash, as many times as needed to get the washing liquid to remove less than 50 g of material per liter of washing liquid; (b) performing an extraction from the solid obtained in step (a) at about room or pressurized pressure, in conditions selected from the group consisting of water between about 80° C.
- step (e) chilling the liquid obtained in step (b) and collecting the resulting precipitate, optionally evaporating part of the solvent before chilling; (d) drying the precipitate obtained in step (c) until the solvent content is lower than about 10% percent by weight; (e) subjecting the product obtained in step (d) to about 120-180° C. for at least 3 minutes; and (f) chilling the product obtained in step (e).
- the starting vegetal material for this process is a commercially dehydrated and crushed pulp.
- pulp without seeds would be preferable, but depending on the fruit or the vegetal variety, seeds could be included.
- Noncommercial vegetal material may have to be washed by water shower and be dried by an air flow before the extraction process. The dried vegetal material may then be crushed by a hammer mill until the size of the constituent particles is less than 3 cm in diameter.
- the washing process of the crushed vegetal material may be performed in diffusion containers or in stirred tanks with water between about room temperature and 60° C.
- the ratio of vegetal material to water is between about 1:4 and 1:10 (w/w).
- the washing may be performed with a mixture of water and a C 1 -C 3 alcohol between about 20:80 and 5:95 (v/v) at room temperature.
- the alcohol is preferably methanol or ethanol and more preferably methanol and the ratio of vegetal material to the mixture of water and methanol is about 1:4 (w/w).
- the washing may also be performed with a mixture of water and acetone between about 20:80 and about 40:60 (v/v) at about room temperature.
- the ratio of water to acetone is about 30:70 (v/v) and the ratio of vegetal material to the mixture of water and acetone is between about 1:2 and 1:3 (w/w).
- the solid and the liquid resulting from the wash may be separated by centrifugation, filtration or decantation, repeating the process from the resulting solid as many times as needed to get the washing liquid to remove less than about 50 g of material per liter of washing liquid, and preferably less than about 10 g of material per liter of washing liquid.
- the vegetal residue from which water-soluble compounds have already been eliminated, may be submerged in a tank with water at a temperature of about 37° C. (between about 1 and about 3 kg of water per kg of wet residue).
- the residue may be added to this tank filled with water, the pH may be rebalanced to about 5 and an enzyme may be added, in particular beta-glucosidase (cellulase), between about 1 and about 25 g per kg of wet residue, depending on the desired magnitude of cellulose hydrolysis, and the mixture may be maintained and stirred at about 37° C. between about 2 and about 4 hours.
- the content of the hydrolysis bath may be decanted or centrifuged, and the supernatant with sugars from the hydrolysis of celluloses may be discarded and the residue may be washed with water at about 50° C. (about 4 kg of water per kg of wet residue), it may be centrifuged again and the supernatant may be discarded.
- an extraction may be performed in diffusing containers or in stirred tanks.
- the extraction may be performed with water between about 80° C. and its boiling point, at conditions of about room or pressurized pressure.
- the ratio of solid versus water may be between about 1:2 and about 1:3 (p/p).
- the extraction may be performed with a C 1 -C 3 alcohol at a temperature between about 40° C. and its boiling point, preferably methanol between about 40° C. and its boiling point, and with a ratio of solid:methanol between about 1:4 and about 1:6 (p/p).
- the extraction may also be performed with a mixture of water and a glycol, preferably propylene glycol, at a temperature between about 80° C. and its boiling point.
- the extraction may also be performed with dimethylformamide between about 80° C. and its boiling point or dimethyl sulphoxide between about 80-150° C.
- the extraction lasts from about 1 to about 4 hours, and more preferably between about 3 and about 4 hours.
- Solid and liquid resulting from the extraction are separated by any suitable method, as decantation, filtration or centrifugation, while keeping the temperature above about 40° C.
- the dark liquid obtained in the previous step may be chilled, usually in decantation tanks.
- the standing time can vary between about 4 and about 10 hours.
- a dark brown precipitate may be formed that corresponds to the fraction of the target proanthocyanidines contained in the vegetal product.
- the precipitate obtained in the previous step is dried, preferably by hot air flow over plates until the solvent content is less than about 10% by weight. In a particular embodiment, the precipitate is dried at about 80-90° C.
- the obtained product is subjected to temperatures of about 120-180° C. for at least for 3 minutes.
- a final product may be obtained with a substantially vitreous aspect, and a brown color, and which is easily broken.
- the product may be milled by hammer mills with a mesh sieve to 0.5 mm until getting a size less than about 180 ⁇ m.
- the product may be passed through a sieve with a mesh of about 180 ⁇ m and the brown colored product may be recovered.
- the product of vegetal origin may provide a pharmaceutical composition comprising a therapeutically effective amount of the product of vegetal origin defined above, together with pharmaceutically acceptable excipients.
- the invention also may provide a dietary complement comprising an effective amount of the product of vegetal origin defined above, together with appropriate amounts of excipients.
- a food product may be provided, which comprises a nutraceutically effective amount of the product of vegetal origin as defined above, together with appropriate amounts of other edible ingredients.
- the most common presentation forms for the pharmaceutical product and the dietary complement may be suspensions, capsules, tablets, powder or pellets; however, this listing does not exclude other forms that the person skilled in the art may consider viable for the administration of the product.
- the food product may be, but is not limited to, a form such as cookies or similar, or a spreadable cream form.
- the product may be used for the preparation of a medicament, a pharmaceutical composition, a dietary complement or a food product for the treatment and/or the prevention of the hypercholesterolaemia and/or cardiovascular diseases in a mammal, including a human.
- This preparation process may be started with about 1000 kg of milled pulp of pomegranate fruit.
- the content in humidity should not be greater than about 10% (w/w) and the size should be less than about 3 cm.
- the milled pulp is treated with water at room temperature at about 1:10 ratio for approximately 4 hours.
- the washing water may be eliminated with the dissolved products passing it through an approximately 100 ⁇ m sieve and the entire solid may be collected and put together with the rest of the solids.
- the previous washing process may be repeated two more times in order to eliminate the water-soluble molecules.
- the temperature of the last wash is increased to about 60° C. for a better extraction of the remains of soluble products. It is advisable to be careful to collect all the solids that remain in the 100 ⁇ m sieve.
- the solid residue may be treated in a tank with reflux, with a mixture of propylene glycol and water in a proportion of about 75:25 (v/v) at about 95° C. for approximately 4 hours to dissolve the proanthocyanidines.
- the hot liquid ( ⁇ 80° C.) is filtered or centrifuged to obtain a dark brown solution that contains the proanthocyanidines. It is concentrated under vacuum at a temperature near about 60° C. until water is eliminated.
- the obtained liquid is cooled to about room temperature (for a minimum of 24 hours).
- the brown precipitate may be recovered by centrifugation and a wet brown-colored paste may be obtained.
- the previous liquid residue may be diluted with cold water in a dilution of about 1 volume of liquid residue to 9 volumes of water.
- the residue may be left for approximately 24 hours and the formed solid recovered by centrifugation. This formed solid may be combined with the solid obtained in the previous step.
- the obtained creamy paste may be spread over plates forming layers not thicker than about 0.5 cm and left in a drying oven at low temperature, not greater than about 80-90° C., until the humidity is reduced to about 10%.
- the oven temperature may be increased to about 150° C. and maintained for about 15 min.
- the obtained product generally has a dark-brown vitreous appearance.
- the obtained product may then be milled to a particle size less than about 170 ⁇ m, and passed through a 100 ⁇ m sieve. The yield is about 1-4% from the milled pomegranate fruit.
- carob bean pulp clean, dried and without seeds.
- An amount of about 100 kg of carob bean pulp may be crushed passing it once through a hammer mill until a size of less than about 3 cm in diameter.
- the crushed product may be placed in stirring tanks, in 400 kg of a mixture of water:methanol in a ratio of about 20:80 (v/v) at room temperature for approximately 2 hours.
- the washing liquid may be discarded, repeating the process several times to eliminate the product of at a rate of less than about 10 g per liter. Later, the solid phase may be separated by decantation.
- the diffusion treatment at about room temperature with a mixture of water:acetone in a ratio of about 30:70 (v/v) (about 2 kg of water per kg of wet residue) may repeated with the solid phase for approximately 3 hours. Later, the extraction liquid may be separated by filtration and discarded.
- the solvent may be evaporated from the residue in vacuum heaters, spreading the residue over plates with a thickness of between about 1 and 1.5 cm and heating at about 45° C. for about 5 hours.
- the obtained solid may be subjected to a stirred diffusion treatment with water (about 2 kg of water per kg of wet residue), at about 100° C. for approximately 3 hours. Later, the extracting liquid may be separated from the insoluble material by hot filtration and the solid residue may be discarded.
- This liquid may be cooled in decantation tanks to attain a temperature of between about 15 and 20° C., maintaining it in such conditions for approximately 6 hours.
- the precipitate may be collected by decantation or centrifugation. The collected amount varies between about 0.2 and 2 kg of dry weight depending on the condition of the fruit.
- the evaporation of the water from the residue may be performed by spreading the residue over plates with a product thickness between about 1 and 1.5 cm, and drying it in heater for approximately 12 hours at about 0.2 atmospheres of pressure and about 85° C., until the water contact drops below about 10%. Finally, when the water content of the residue drops below about 10%, the dried product may be subjected to a temperature of about 180° C. in an air flow for approximately 3 minutes, followed by chilling at room temperature.
- the product when cooled, may be milled in hammer mills with a mesh of less then about 0.5 mm until the product particles are less than 180 ⁇ m in diameter.
- the product may be passed through a sieve with a net size of 180 ⁇ m and the finished product may be obtained.
- Influence over cholesterolaemia in rats was studied with three types of dietary fiber and the product of vegetal origin of the invention: microcrystalline cellulose (CEL) AVICEL®, carob fiber (CF) from C.G.A. S.A., modified polyphenols (MP) according to the patent document ES 2.187.356 and the product of vegetal origin (PVO) described herein.
- the fibers were included in four semi-synthetic isocaloric diets adjusted to the nutritional needs of the rats.
- the base-diet used was AIN 93-G #110113 Purified Diet (Dyets Inc., Pennsylvania), and the only variable was the type of food fiber, always in a proportion of 5% of the diet.
- “Wistar” male rats were used, from the Servicio de Animales del Centro Mixto Departamento de Nutri Terms y Bromatologia I and from Instituto de Nutri Terms CSIC-UCM (Facultad de Farmacia U.C.M.), selected from the same litter.
- 40 young rats were used to develop an experimental cholesterolaemia provoked by the consumption of cholesterol in the amounts of 8 g/kg of diet and bovine bile 2 g/kg of diet, both from Farmitalia-Carlo Erba, Madrid, together with their maintaining diet, for a period of fifteen days.
- the animals were placed in individual metabolism cells. The metabolism cells were kept in a room at 22 ⁇ 2° C., with an automatic light-darkness control (12:12 hours) and constant air circulation.
- Rats were divided into 4 groups of 10 hypercholesterolaemiac rats (serum cholesterol 250 ⁇ 37 mg/dl). Each group, otherwise kept in the same conditions, consumed the cholesterol-supplemented diet for 20 days more, but included in their diet one of each of the assayed fibers at the level of 5%.
- the initial serum cholesterol was determined by extracting blood from the tail vein of the animal by puncture, after a vasodilatation in a bath at 37° C. Blood was collected in a capillary tube treated with heparin, and cholesterol was quantified immediately by an automatic analyzer. Cholesterol after the 20 days was determined in serum by cannulating the jugular vein, after anaesthetizing the animals.
- Product 1 corresponds to the product described herein. This product has been obtained following the process described above.
- Product 2 corresponds to a product previously known in the art. This product was obtained following the process described in the PCT application number WO2004/014150A.
- product 1 has a more pronounced effect on serum cholesterol in humans than a carob pulp preparation obtained following the process described in WO2004/014150A (product 2).
- an effective amount of product 1 (about 50% lower than the amount of the product 2) achieves a reduction in the total cholesterol of more than two hundred fold better than the reduction achieved with product 2.
Abstract
Description
-
- Humidity: about 0-10%
- Minerals: about 2-10%
- Proanthocyanidines with molecular weight greater than 6000 daltons: about 65-97% (proanthocyanidines with molecular weight greater than 30000 daltons: more than about 50% of said proanthocyanidines)
- Water-soluble polyphenols: about 0-2%.
- Celluloses and hemicelluloses: about 0-5%.
- Lignin: about 0-10%
- Oligosaccharides: about 0-5%
- Proteins: about 0-5%
TABLE 1 |
shows the evolution of cholesterolaemia of rats with experimental |
hypercholesterolaemia that took diets including microcrystalline cellulose |
(CEL), carob fiber (CF), modified polyphenols (MP) and the product of |
vegetal origin of the invention (PVO). |
serum cholesterol (mg/dl) | serum cholesterol (mg/dl) | |
day 0 | day 20 | |
PVO | 250 ± 37 | 125 ± 18abc | |
CEL | 250 ± 37 | 275 ± 25 | |
MP | 250 ± 37 | 140 ± 10ab | |
CF | 250 ± 37 | 180 ± 20ab | |
An aindicates significant difference (p < 0.05) from the CEL lot; | |||
a bindicates a significant difference (p < 0.05) from basal hypercholesterolaemia, and | |||
a cindicates a significant difference (p < 0.05) from the MP lot. |
Comparative Study: Comparison of the Effects of the Product of the Present Invention Over Those Generated by a Product Obtained Following the Process of WO2004/014150A
TABLE 1 | |||||
Reductions | |||||
on mean | |||||
Adult | total | ||||
volunteers | Doses | Treatment | Placebo | cholesterol | |
Product | (number) | (g/day) | (days) | group | (%) |
Product 2 | 47 | 15 g | 28 | No | 7% |
Product 2 | 58 | 15 g | 28 | Yes | 9% |
Product 1 | 45 | 6 g | 28 | No | 30% |
Product 1 | 60 | 8 g | 28 | Yes | 23% |
Claims (21)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200401626A ES2245610B1 (en) | 2004-06-23 | 2004-06-23 | PRODUCT OF VEGETABLE ORIGIN AND ITS OBTAINING PROCEDURE. |
ES200401626 | 2004-06-23 | ||
ESP200401626 | 2004-06-23 | ||
PCT/EP2005/052877 WO2006000551A1 (en) | 2004-06-23 | 2005-06-21 | Product of vegetal origin comprising proanthocyanidines and its preparation process |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080063733A1 US20080063733A1 (en) | 2008-03-13 |
US8663708B2 true US8663708B2 (en) | 2014-03-04 |
Family
ID=34972296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/571,237 Active 2028-08-08 US8663708B2 (en) | 2004-06-23 | 2005-06-21 | Product of vegetal origin comprising proanthocyanidines and its preparation process |
Country Status (16)
Country | Link |
---|---|
US (1) | US8663708B2 (en) |
EP (1) | EP1768682B1 (en) |
JP (1) | JP2008503542A (en) |
AT (1) | ATE410173T1 (en) |
AU (1) | AU2005256621B2 (en) |
CA (1) | CA2570989A1 (en) |
DE (1) | DE602005010256D1 (en) |
DK (1) | DK1768682T3 (en) |
ES (2) | ES2245610B1 (en) |
MA (1) | MA28668B1 (en) |
NZ (1) | NZ552709A (en) |
PL (1) | PL1768682T3 (en) |
PT (1) | PT1768682E (en) |
TN (1) | TNSN06428A1 (en) |
WO (1) | WO2006000551A1 (en) |
ZA (1) | ZA200700559B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2570433B1 (en) * | 2014-10-17 | 2016-11-21 | Universitat Rovira I Virgili | USE OF PROANTOCIANIDINS FOR THE SUPPRESSION OF THE APPETITE OR INDUCTION OF THE COMPANY |
ES2602877B1 (en) * | 2015-07-22 | 2017-12-01 | Consejo Superior De Investigaciones Científicas (Csic) | PROCEDURE FOR OBTAINING A CONCENTRATE OF POLYMER PROANTOCIANIDINS WITH A CONTENT OVER 90% THROUGH ENZYMATIC TREATMENTS AND WITHOUT USING ORGANIC SOLVENTS |
CN107595893A (en) * | 2017-08-25 | 2018-01-19 | 广西中医药大学 | A kind of enzyme treated prepared slices of Chinese crude drugs and preparation method thereof |
KR20220169986A (en) * | 2021-06-22 | 2022-12-29 | 주식회사 세이브앤코 | Methods for extracting anthocyanins to improve urinary health by using cranberries and plant-based lactobacillus which enhance female reproductive health and extracts of thereby |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3950553A (en) * | 1974-06-10 | 1976-04-13 | Societe D'assistance Technique Pour Produits Nestle S.A. | Process for preparing a soluble tea product |
US4282264A (en) * | 1979-01-26 | 1981-08-04 | Societe D'assistance Technique Pour Produits Nestle S.A. | Process for removing bitter taste from a fruit or vegetable extract, and the debittered extract thus obtained |
WO1990013304A1 (en) | 1989-05-12 | 1990-11-15 | Institut Des Substances Vegetales | Proanthocyanidol-based composition and its pharmacological application |
EP0713706A2 (en) | 1994-11-28 | 1996-05-29 | Suntory Limited | Lipoprotein (a) lowering agent, cholesterol lowering agent and medicaments comprising these agents respectively |
US6361807B1 (en) * | 1999-04-19 | 2002-03-26 | Stewart And Lynda Resnick Revocable Trust | Pomegranate extracts and methods of using thereof |
US20030077374A1 (en) * | 2001-09-28 | 2003-04-24 | Kao Corporation | Beverages |
WO2004014150A1 (en) | 2002-08-06 | 2004-02-19 | Investigacion Y Nutricion, S.L. | Denatured carob flour (dcf) with a low content of soluble tannins and sugars, meant for human consumption and process to obtain it |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59196884A (en) * | 1983-04-20 | 1984-11-08 | Nippon Shinyaku Co Ltd | Novel tannin |
US5211944A (en) * | 1990-10-12 | 1993-05-18 | Shaman Pharmaceuticals, Inc. | Proanthocyanidin polymers having antiviral activity and methods of obtaining same |
JP2000247896A (en) * | 1999-02-26 | 2000-09-12 | Snow Brand Milk Prod Co Ltd | Bone quantity reduction-inhibitory composition |
US6500469B1 (en) * | 2000-04-20 | 2002-12-31 | Dry Creek Nutrition, Inc. | Methods and compositions for reducing cholesterol levels using a proanthocyanidin and niacin-bound chromium complex |
JP4921681B2 (en) * | 2001-11-14 | 2012-04-25 | 川澄化学工業株式会社 | Preventive drugs |
-
2004
- 2004-06-23 ES ES200401626A patent/ES2245610B1/en not_active Expired - Fee Related
-
2005
- 2005-06-21 EP EP05760934A patent/EP1768682B1/en active Active
- 2005-06-21 AT AT05760934T patent/ATE410173T1/en active
- 2005-06-21 DK DK05760934T patent/DK1768682T3/en active
- 2005-06-21 JP JP2007517287A patent/JP2008503542A/en active Pending
- 2005-06-21 DE DE602005010256T patent/DE602005010256D1/en active Active
- 2005-06-21 NZ NZ552709A patent/NZ552709A/en not_active IP Right Cessation
- 2005-06-21 ES ES05760934T patent/ES2318508T3/en active Active
- 2005-06-21 PL PL05760934T patent/PL1768682T3/en unknown
- 2005-06-21 US US11/571,237 patent/US8663708B2/en active Active
- 2005-06-21 CA CA002570989A patent/CA2570989A1/en not_active Abandoned
- 2005-06-21 AU AU2005256621A patent/AU2005256621B2/en not_active Ceased
- 2005-06-21 PT PT05760934T patent/PT1768682E/en unknown
- 2005-06-21 WO PCT/EP2005/052877 patent/WO2006000551A1/en active Application Filing
-
2006
- 2006-12-15 MA MA29537A patent/MA28668B1/en unknown
- 2006-12-22 TN TNP2006000428A patent/TNSN06428A1/en unknown
-
2007
- 2007-01-19 ZA ZA2007/00559A patent/ZA200700559B/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3950553A (en) * | 1974-06-10 | 1976-04-13 | Societe D'assistance Technique Pour Produits Nestle S.A. | Process for preparing a soluble tea product |
US4282264A (en) * | 1979-01-26 | 1981-08-04 | Societe D'assistance Technique Pour Produits Nestle S.A. | Process for removing bitter taste from a fruit or vegetable extract, and the debittered extract thus obtained |
WO1990013304A1 (en) | 1989-05-12 | 1990-11-15 | Institut Des Substances Vegetales | Proanthocyanidol-based composition and its pharmacological application |
EP0713706A2 (en) | 1994-11-28 | 1996-05-29 | Suntory Limited | Lipoprotein (a) lowering agent, cholesterol lowering agent and medicaments comprising these agents respectively |
US6361807B1 (en) * | 1999-04-19 | 2002-03-26 | Stewart And Lynda Resnick Revocable Trust | Pomegranate extracts and methods of using thereof |
US20030077374A1 (en) * | 2001-09-28 | 2003-04-24 | Kao Corporation | Beverages |
WO2004014150A1 (en) | 2002-08-06 | 2004-02-19 | Investigacion Y Nutricion, S.L. | Denatured carob flour (dcf) with a low content of soluble tannins and sugars, meant for human consumption and process to obtain it |
Non-Patent Citations (11)
Title |
---|
Abu Bakr Mahammad Bin Zakariyya Al-Razi; Kitaab-al-Haawi-fil-Tibb, vol. XX (9th century AD), Dayerah-al-Ma'aarif Usmania, Hyderabad (First Edition) 1967 AD p. 516 Formulation ID: AAA20/5870 Formulation Name: Dawa Bara-e-Khafaqaan. |
Agnivesa; Caraka Samhita-Edited and translated by P.V. Sharma, vol. II: Chaukamba Orientalia Varanasi Edn. 5th, 2000 [Time of origin 1000 BC-4th century] p. 340 Formulation ID: BP/2643C Formulation Name: Apatantrakaharahinguvadiyogah. |
European Patent Office, Examination Report for International Application No. 05 760 934.9, Jan. 31, 2008. |
Mahendra Bhaugika; Dhanvantarinighantauh Edited by P.V. Sharma; Translated by Guru Prasad Sharma; Chaukhambha Orientalia, Varanasi Edn. 3rd, 2002 p. 81 Formulation ID: AK12/184 Formulation Name: Dadima GUna. |
Marakis S: "Carbo Bean in Food and Feed: Current Status and Future Potentials-a Critical Appraisal", Journal of Food Science and Technology, Association of Food Scientists and Technologists, US, vol. 33, No. 5, 1996, pp. 365-383, Athens, Greece. |
Mohammad Azam Khan; Muheet Azam vol. II (Part II) (19th century AD), Matba Nizami, Kanpur, 1898 AD p. 5-6 Formulation ID: AA26109 Formluation Name: Daaram/anar. |
Mohammad Kabiruddin, Bayaaz-e-Kabir, vol. II (Compiled) Daftar-al-Maseeh, Karol Bagh New Delhi, 1938 AD p. 75 Formulation ID: MA3/232 Formulation Name: Rubb-e-Anaar Sheerin. |
Mohammand Akbar Arzani: Qaraabaadeen Qaadri (17th centurty AD), Ahmadi Publication, Delhi, 1968 AD p. 213 Formulation ID: MH5/1476 Formulation Name: Safoof-e-Loolooee. |
Response to the Examination Report for International Application No. 05 760 934.9, Feb. 18, 2008, with attachments Annex-1 and Annex-2. |
Sarngadharacarya; sarngadhara Samhita. Translated by Smt. Shailaja Srivastava: Chaukhamba Orientalia, Varanasi, Edn. 2nd, 1998 [Time of origin 13th century] p. 188 Formulation ID: AT/229. Formulation Name: Sunthyadicurna. |
Wursch P et al: "Tannin Granules from Ripe Carob Ceratonia-Siliqua Pod", Lebensrnittel-Wissenschaft and Technologie, vol. 17, No. 6, 1984, pp. 351-354, La Tour de Peilz, Switzerland. |
Also Published As
Publication number | Publication date |
---|---|
ES2245610B1 (en) | 2007-03-16 |
DE602005010256D1 (en) | 2008-11-20 |
ATE410173T1 (en) | 2008-10-15 |
TNSN06428A1 (en) | 2008-02-22 |
EP1768682B1 (en) | 2008-10-08 |
ZA200700559B (en) | 2008-04-30 |
NZ552709A (en) | 2009-10-30 |
JP2008503542A (en) | 2008-02-07 |
US20080063733A1 (en) | 2008-03-13 |
DK1768682T3 (en) | 2009-02-16 |
PT1768682E (en) | 2009-01-20 |
MA28668B1 (en) | 2007-06-01 |
EP1768682A1 (en) | 2007-04-04 |
ES2318508T3 (en) | 2009-05-01 |
WO2006000551A1 (en) | 2006-01-05 |
AU2005256621B2 (en) | 2010-03-18 |
AU2005256621A1 (en) | 2006-01-05 |
ES2245610A1 (en) | 2006-01-01 |
PL1768682T3 (en) | 2009-04-30 |
CA2570989A1 (en) | 2006-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8663708B2 (en) | Product of vegetal origin comprising proanthocyanidines and its preparation process | |
CN110201067A (en) | A kind of Ampelopsis grossedentata extrat and its preparation method and application | |
CN113480676B (en) | Oligogalacturonic acid polysaccharide, compound, preparation method and application thereof | |
CN100506238C (en) | Composition of bitter melon polysaccharide for reducing blood sugar, and preparation method | |
KR101729003B1 (en) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus | |
KR101517833B1 (en) | A composotion for the treatment of dyslipidemia comprising the red ginseng complex | |
US10561700B2 (en) | Use of overground part of Hedychium coronarium Koenig in reducing blood glucose; extracts and compositions of overground part of Hedychium coronarium Koenig and their uses | |
WO2020091265A1 (en) | Composition comprising elderberry extract as effective component for preventing, treating, or alleviating male climacteric syndrome | |
US8642096B2 (en) | Pharmaceutical composition containing herbal extract for prevention or treatment of nephritis | |
KR20170095646A (en) | Manufacturing method of composition having anti-diabetic effect containing the extracts of fermented germinated brown rice and orstachys japonia | |
CN102228666B (en) | Composition prepared from pine pollen and curcuma, preparation method thereof, and application of composition in preparing medicament for treating inflammatory bowel disease | |
CN106822338A (en) | Compound of reducing blood sugar and blood fat, prevention and/or treatment diabetes and its complication and application thereof | |
CN107890528A (en) | A kind of Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
KR101131719B1 (en) | Pulsatilla koreana extracts compositions for treating or preventing inflammatory diseases | |
KR102172371B1 (en) | A pharmaceutical composition comprising extract of Aloe, quince and corn silk for preventing or treating obesity | |
CN114601891B (en) | Composition with anti-ulcerative colitis effect and preparation method thereof | |
CN116392527A (en) | A medicinal and edible product for improving chronic kidney disease | |
KR101860510B1 (en) | Composition for Improving Retinal Diseases Using an Extract of Lithospermum erythrorhizon | |
CN112439012A (en) | Health-care granules for preventing and treating diabetes, hyperglycemia and hypertension and preparation method thereof | |
CN111821326A (en) | Application of photorhabdus alternatus flower | |
KR20220084833A (en) | Composition for Anti-Diabetes Using an Extract of Ampelocissus polythyrsa | |
WO2022205518A1 (en) | Method for preparing pandanus tectorius polysaccharide | |
CN117562934A (en) | Application of pharmaceutical composition in preparation of medicine for preventing and/or treating type II diabetes | |
CN117899175A (en) | Traditional Chinese medicine prescription for reducing blood sugar and uric acid and preparation method thereof | |
CN114392293A (en) | Preparation method of Codonopsis lanceolata extract and application of Codonopsis lanceolata extract in preventing and treating kidney injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INVESTIGACION Y NUTRICION, S.I., SPAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RUIZ-ROSO CALVO DE MORA, BALTASAR;REEL/FRAME:018672/0990 Effective date: 20061031 |
|
AS | Assignment |
Owner name: WILD VALENCIA, S.A., SPAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INVESTIGACION Y NUTRICION, S.L.;REEL/FRAME:028492/0197 Effective date: 20120110 |
|
AS | Assignment |
Owner name: INVESTIGACION Y NUTRICION, S.L., SPAIN Free format text: ASSIGNOR ASSIGNS 50 PERCENT INTEREST;ASSIGNOR:INVESTIGACION Y NUTRICION, S.L.;REEL/FRAME:028701/0985 Effective date: 20120110 Owner name: WILD VALENCIA, S.A., SPAIN Free format text: ASSIGNOR ASSIGNS 50 PERCENT INTEREST;ASSIGNOR:INVESTIGACION Y NUTRICION, S.L.;REEL/FRAME:028701/0985 Effective date: 20120110 |
|
AS | Assignment |
Owner name: WILD VALENCIA, S.A., SPAIN Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYANCE TO READ "ASSIGNOR ASSIGNS 50 PERCENT INTEREST" PREVIOUSLY RECORDED ON REEL 028492 FRAME 0197. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INVESTIGACION Y NUTRICION, S.L.;REEL/FRAME:032019/0191 Effective date: 20120110 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: WILD VALENCIA, S.A., SPAIN Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 028701 FRAME 0985. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT FROM ASSIGNOR INVESTIGACION Y NUTRICION, S.L. OF 50% INTEREST TO ASSIGNEE WILD VALENCIA, S.A.;ASSIGNOR:INVESTIGACION Y NUTRICION, S.L.;REEL/FRAME:032376/0410 Effective date: 20120110 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551) Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |